Short answer: Both are once-daily SGLT2 inhibitor tablets.12 Steglatro (ertugliflozin) is approved only for blood sugar control in adults with type 2 diabetes, at 5 mg up to 15 mg each morning. Farxiga (dapagliflozin) is also approved for blood sugar from age 10, and for chronic kidney disease and heart failure in adults, with or without diabetes. Neither has a boxed warning, and neither label reports a trial against the other.
| Steglatro | Farxiga | |
|---|---|---|
| Drug | Ertugliflozin1 | Dapagliflozin2 |
| Approved for | Blood sugar control in adults with type 2 diabetes1 | Blood sugar in adults and children 10 and older with type 2 diabetes; chronic kidney disease and heart failure in adults; heart failure hospital stays in adults with type 2 diabetes and heart disease or risk factors2 |
| Dose | 5 mg once daily in the morning; 15 mg if tolerated and more control is needed1 | Blood sugar: 5 mg, up to 10 mg; kidney and heart uses: 10 mg2 |
| Kidney limits | Not recommended below an eGFR of 451 | For blood sugar, not recommended below an eGFR of 45; kidney and heart uses not started below 252 |
| Before surgery with long fasting | Held at least 4 days if possible1 | Held at least 3 days if possible2 |
| Side effects in label trials | Pooled 26-week trials: female genital yeast infection 9.1% on 5 mg and 12.2% on 15 mg vs 3.0% on placebo1 | 12-trial pool: female genital yeast infection 8.4% on 5 mg and 6.9% on 10 mg vs 1.5% on placebo2 |
| Boxed warning | None1 | None2 |
Mostly. Both labels list ketoacidosis even with blood sugar below 250 mg/dL, fluid loss and kidney injury, urinary and genital infections including Fournier's gangrene, and low blood sugar with insulin or a sulfonylurea.12 The Steglatro label also lists lower limb amputation: 4.7, 5.7 and 6.0 events per 1,000 patient-years on placebo, 5 mg and 15 mg in its long-term heart outcomes study.1 These numbers come from separate trials with different people, lengths and methods, so they are not a head-to-head comparison.
Which, if either, fits is for your prescriber. More detail: Steglatro side effects, Farxiga side effects, the Steglatro and Farxiga dosing schedules, the Steglatro and Farxiga missed-dose pages, Steglatro vs Jardiance: how do the two SGLT2 tablets differ? and Jardiance vs Farxiga: how do the two SGLT2 tablets compare?.